Balance Sheet for ANEB - findataslice

	Anebulo Pharmaceuticals, Inc.
	Q4-CY2025	Q3-CY2025	Q2-CY2025	Q1-CY2025	Q4-CY2024	Q3-CY2024	Q2-CY2024	Q1-CY2024	Q4-CY2023	Q3-CY2023	Q2-CY2023	Q1-CY2023	Q4-CY2022	Q3-CY2022	Q2-CY2022	Q1-CY2022	Q4-CY2021	Q3-CY2021	Q2-CY2021	Q1-CY2021	Q4-CY2020	Q3-CY2020	Q2-CY2020	Q1-CY2020	Q4-CY2019	Q3-CY2019	Q2-CY2019	Q1-CY2019	Q4-CY2018	Q3-CY2018	Q2-CY2018	Q1-CY2018	Q4-CY2017	Q3-CY2017	Q2-CY2017	Q1-CY2017	Q4-CY2016	Q3-CY2016	Q2-CY2016	Q1-CY2016	Q4-CY2015	Q3-CY2015	Q2-CY2015	Q1-CY2015	Q4-CY2014	Q3-CY2014	Q2-CY2014	Q1-CY2014	Q4-CY2013
Balance Sheet Date			2025-Jun-30	2025-Mar-31	2024-Dec-31	2024-Sep-30	2024-Jun-30	2024-Mar-31	2023-Dec-31	2023-Sep-30	2023-Jun-30	2023-Mar-31	2022-Dec-31	2022-Sep-30	2022-Jun-30	2022-Mar-31	2021-Dec-31	2021-Sep-30		2021-Mar-31
Fiscal Period			Q4-FY2025	Q3-FY2025	Q2-FY2025	Q1-FY2025	Q4-FY2024	Q3-FY2024	Q2-FY2024	Q1-FY2024	Q4-FY2023	Q3-FY2023	Q2-FY2023	Q1-FY2023	Q4-FY2022	Q3-FY2022	Q2-FY2022	Q1-FY2021		Q3-FY2020
Total Assets			12,145,616$	14,008,484$	15,841,220$	2,467,940$	4,073,114$	5,995,635$	7,500,773$	9,047,884$	11,670,151$	14,432,606$	16,888,256$	19,815,365$	15,579,431$	17,248,467$	18,963,871$	20,500,342$		4,291,475$			3,028,480$
Total Current Assets			11,962,506$	13,807,935$	15,395,489$	1,962,513$	3,507,990$	5,370,815$	6,816,257$		11,670,151$									3,898,745$			3,028,480$
Cash and Cash Equivalents			11,627,849$	13,279,901$	14,998,467$	1,404,211$	3,094,200$	5,147,139$	6,644,517$	8,520,578$	11,247,403$									3,307,083$			3,024,980$
Receivables
Other Current Assets
Assets Held for Sale in Short Term
Total Noncurrent Assets			183,110$	200,549$	445,731$	505,427$	565,124$	624,820$	684,516$	9,047,884$	0$	14,432,606$	16,888,256$	19,815,365$	15,579,431$	17,248,467$	18,963,871$	20,500,342$		392,730$			0$
Goodwill
Other Intangible Assets
Physical Assets
Other Noncurrent Assets			183,110$	200,549$	445,731$	505,427$	565,124$	624,820$	684,516$
Assets Held for Sale in Long Term
Total Liabilities			487,688$	546,032$	878,799$	569,225$	260,583$	1,010,321$	1,013,556$	716,560$	1,068,801$	1,491,085$	1,372,401$	698,179$	512,531$	85,777$	49,944$	607,706$		10,751,559$			223,865$
Total Current Liabilities																				293,166$			223,865$
Accounts Payable			224,175$	427,578$	319,515$	252,142$	156,426$	384,920$	318,679$	565,949$	534,545$	570,902$	346,554$	523,473$	380,828$	83,277$	42,944$	493,819$		82,027$
Short Term Debt
Short Term Capital Lease Obligations
Other Current Liabilities												30,750$	30,750$	5,116$
Total Noncurrent Liabilities			487,688$	546,032$	878,799$	569,225$	260,583$	1,010,321$	1,013,556$	716,560$	1,068,801$	1,491,085$	1,372,401$	698,179$	512,531$	85,777$	49,944$	607,706$		10,458,393$			0$
Long Term Debt
Long Term Capital Lease Obligations
Other Noncurrent Liabilities
Total Equity			11,657,928$	13,462,452$	14,962,421$	1,898,715$	3,812,531$	4,985,314$	6,487,217$	8,331,324$	10,601,350$	12,941,521$	15,515,855$	19,117,186$	15,066,900$	17,162,690$	18,913,927$	19,892,636$		(9,435,836$)	(719,018$)	(411,108$)	(171,137$)
Equity to Minority
Equity to Common Shareholders			11,657,928$	13,462,452$	14,962,421$	1,898,715$	3,812,531$	4,985,314$	6,487,217$	8,331,324$	10,601,350$	12,941,521$	15,515,855$	19,117,186$	15,066,900$	17,162,690$	18,913,927$	19,892,636$		(9,435,836$)	(719,018$)	(411,108$)	(171,137$)
Additional Paid-In Capital			85,505,349$	85,165,045$	84,988,845$	69,477,261$	69,190,341$	69,013,155$	68,861,516$	67,988,554$	67,777,757$	67,622,348$	67,398,711$	67,173,090$	60,513,258$	60,286,306$	60,161,052$	60,066,770$		83,526$
Retained Earnings			(73,888,507$)	(71,743,679$)	(70,067,510$)	(67,604,480$)	(65,403,744$)	(64,053,775$)	(62,400,233$)	(59,682,864$)	(57,202,041$)	(54,706,461$)	(51,908,490$)	(48,081,538$)	(45,469,703$)	(43,146,961$)	(41,270,470$)	(40,197,479$)		(9,532,345$)			(183,137$)
Treasury Stock
Capital Lease Obligations